Ernexa Therapeutics Inc. Stock Analysis & AI Score
Ernexa Therapeutics Inc. (ERNA) has an ST Score of 23.6 (D+), driven by its Growth (B) and held back by its Momentum (F). ERNA last traded at $3.62.
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Ernexa Therapeutics Inc. (ERNA) has an ST Score of 23.6 (D+), driven by its Growth (B) and held back by its Momentum (F). ERNA last traded at $3.62.
- Strongest
- GrowthB
- Weakest
- MomentumF
All factor grades
- GrowthB
- ValuationC+
- Financial StrengthD-
- ProfitabilityF
- MomentumF
- Piotroski2/9
Contact
ERNA stock: frequently asked questions
What is ERNA's ST Score?
Ernexa Therapeutics Inc. (ERNA) has an ST Score of 23.6 (D+), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is ERNA a buy, hold, or sell?
Our ST Score grades it D+ (23.6/100). The ST Score is a data-driven signal, not a recommendation.
What are ERNA's factor grades?
Valuation C+, Profitability F, Financial Strength D-, Momentum F, Growth B.
What is ERNA's valuation grade?
Ernexa Therapeutics Inc. (ERNA) earns a valuation grade of C+, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is ERNA's growth grade?
Ernexa Therapeutics Inc. (ERNA) earns a growth grade of B, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is ERNA's profitability grade?
Ernexa Therapeutics Inc. (ERNA) earns a profitability grade of F, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is ERNA's financial strength grade?
Ernexa Therapeutics Inc. (ERNA) earns a financial strength grade of D-, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is ERNA's Piotroski score?
Ernexa Therapeutics Inc. (ERNA) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.